GCIA
DMII

Gabelli & Co Investment Advisers’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.79M Buy
+179,500
New +$1.79M 0.27% 80

Other funds holding DMII

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Gabelli & Co Investment Advisers's DMII Position: Q1 2026 in Review

Gabelli & Co Investment Advisers opened a new position in Drugs Made In America Acquisition II Corp (DMII) in Q1 2026: 179,500 shares worth $1.79M. The stake represents 0.27% of the portfolio and ranks #80 among its holdings.

68 funds tracked by Wall St. Rank hold DMII as of Q1 2026.

  • Gabelli & Co Investment Advisers held 179,500 shares of Drugs Made In America Acquisition II Corp worth $1.79M as of Q1 2026.
  • Drugs Made In America Acquisition II Corp was a new Gabelli & Co Investment Advisers position in Q1 2026.
  • Drugs Made In America Acquisition II Corp made up 0.27% of Gabelli & Co Investment Advisers's portfolio in Q1 2026, its #80 holding.
  • 68 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q1 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.